Figure 7 demonstrates the mechanism of action of ACOX1-specific inhibitors and their ability to improve OCA efficacy while reducing toxicity in NAFLD treatment. This evidence concerns the gene ACOX1 and metabolic dysfunction-associated steatotic liver disease.